Chan’s research interests are at the interface of how viruses and the human immune system interact, with a focus on molecular engineering of desired viral and immune functions. He is currently working with George Church on a project at the Wyss Institute’s Synthetic Biology platform to develop safer and more efficacious AAV-based gene therapies. Kai received his Ph.D. in Microbiology and Immunobiology from Harvard University in 2015, with a certificate in Human Biology and Translational Medicine. During his Ph.D. in Michaela Gack’s lab, he uncovered a novel phosphomimetic-based mechanism that is used by dengue virus to subvert the host immune response, and engineered a live attenuated dengue virus. Prior, he received his M.S. from Stanford University and B.A., summa cum laude, from Washington University in St. Louis.